Alluvi, known as BI 4744, offers a notable advance in obesity therapy. This dual activator targeting both glucagon-like peptide-1 and GIP receptors demonstrates remarkable efficacy in patient trials, arguably exceeding https://bookmarkinglog.com/story22183910/alluvi-a-detailed-dive-into-the-retatrutide-s-prospects